Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
Authors' conclusion
In real-life conditions, the GLP-1RA/SGLT2i combination reduced cardiovascular and renal outcomes compared with both GLP-1RA monotherapy and SGLT2i monotherapy. Overall, observational studies confirm the results reported in post-hoc exploratory analyses of RCTs versus placebo.
Study context
- Population
- Patients with T2D in real-life clinical practice, including patients with atherosclerotic CVD and/or HF9 observational studies
- Comparison
- GLP-1 RA/SGLT2i combination vs GLP-1 RA monotherapy or SGLT2i monotherapy, in addition to standard of care
- Outcome
- Cardiovascular outcomes: MACE, hospitalization for HF, all-cause mortality
Pooled result
As reported in the abstract
- Combination associated with greater reduction in MACE, hospitalization for HF and all-cause mortality vs either GLP-1 RA alone or SGLT2i alone
- No obvious differences between the two monotherapies, including regarding HF
Further pooled results
- Greater benefit with combination vs GLP-1 RA alone or SGLT2i alone
- Only 3 observational studies reported renal outcomes
Original publication
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab. Published 26 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →